Tirzepatide to prevent irregular heartbeat after heart procedure
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study tests whether a weekly injection of tirzepatide (a medicine that helps with weight loss and blood sugar) can lower the chance of atrial fibrillation coming back after a heart procedure called catheter ablation. It may help people who are overweight or have obesity and are having this procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a type of irregular heartbeat called persistent atrial fibrillation (lasting more than a week) and are scheduled for a first-time catheter ablation (a procedure to fix the rhythm).
- Your body mass index (BMI) is 27 or higher, and you have at least one weight-related condition such as heart disease, high blood pressure, high cholesterol, or prediabetes.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use reliable birth control during the study.
- You do not have certain heart conditions, recent heart surgery, active infections, or a history of thyroid cancer or pancreatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a weight-loss medication called tirzepatide (given as a shot) helps prevent atrial fibrillation from coming back after a catheter ablation procedure. It is for people who have both obesity and atrial fibrillation, and it may help improve heart health by reducing weight and inflammation.
This study tests whether tirzepatide, a medication that helps with weight loss and blood sugar control, can improve the ability to exercise and daily function in people who have heart failure with reduced pumping strength and are overweight or obese.
This study tests whether the medicine tirzepatide can help adults who are overweight or obese and have congenital heart disease (a heart condition present from birth) lose weight safely. The medicine may also improve heart health and metabolism. It is for people who have already tried diet and exercise for at least a year without much weight loss.
This study tests whether combining a weight-loss medication called tirzepatide (also known as Mounjaro) with a supervised exercise program helps people lose weight and improve their overall health. You'll be in the study for about four months, and you'll get support and monitoring.
This study looks at whether losing weight can help reduce the progression of atrial fibrillation (an irregular heartbeat). It might help people who are overweight and have AF symptoms.
This study looks at how well the medicine tirzepatide works in real life for adults who are overweight (BMI 30 or more) and have prediabetes or type 2 diabetes. It aims to see if the medicine helps control blood sugar and weight, and it's important that you have had a recent eye exam before starting.
Hear when a new Atrial Fibrillation Ablation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.